Skip to main content

Table 7 Adjusted changes in weight, fasting plasma glucose, and HbA1c at 12 and 24 months by participants achieving higher ‘dose’ of intervention (moderate, or high) compared to lowest dose participants in each intervention group

From: Effects of the Norfolk diabetes prevention lifestyle intervention (NDPS) on glycaemic control in screen-detected type 2 diabetes: a randomised controlled trial

 

Intervention group

Intervention group-DPM

Moderate dose

p

High dose

p

Moderate dose

p

High dose

p

12 months

 HbA1c (mmol/mol)

  Adjusted

1.69 (−3.4, 6.7)

0.50

−3.45 (−7.69, 0.78)

0.11

−3.00 (−6.88, 0.89)

0.13

−3.17 (−6.72, 0.38)

0.08

 HbA1c (mmol/mol)

  Unadjusted

−1.43 (−8.8, 6.0)

0.70

−8.96 (−15.6, −2.3)

0.01

0.9 (−3.81, 5.62)

0.70

1.56 (−2.7, 5.8)

0.47

 Weight (kg)

  Adjusted

1.36 (−2.5, 5.3)

0.48

−3.6 (−6.9, −0.2)

0.04

−0.73 (−4.67, 3.22)

0.71

−1.03 (−4.55, 2.49)

0.56

 Weight (kg)

  Unadjusted

−1.06 (−4.2, 2.1)

0.51

−3.28 (−6.1, −0.4)

0.02

0.72 (−2.2, 3.7)

0.63

−0.07 (−2.69, 2.54)

0.96

 Fasting plasma glucose (mmol/l)

  Adjusted

0.40 (−0.44, 1.23)

0.34

0.06 (−0.65, 0.76)

0.88

−0.08 (−0.85, 0.68)

0.83

−0.06 (−0.76, 0.64)

0.87

 Fasting plasma glucose (mmol/l)

  Unadjusted

−0.62 (−1.8,0.56)

0.30

−1.2 (−2.25, −0.15)

0.03

0 (−0.8, 0.79)

0.99

0.15 (−0.57, 0.86)

0.68

24 months

 HbA1c (mmol/mol)

  Adjusted

−0.05 (−5.09, 5.00)

0.99

−3.77 (−8.31, 0.78)

0.10

4.71 (−1.62, 11.04)

0.14

2.29 (−3.44, 8.03)

0.42

 HbA1c (mmol/mol)

  Unadjusted

−0.21 (−6.9, 6.4)

0.95

−2.74 (−8.9, 3.5)

0.38

3.51 (−2.9, 9.9)

0.277

1.77 (−4.13, 7.67)

0.55

 Weight (kg)

  Adjusted

−2.18 (−7.41, 3.06)

0.40

−5.19 (−9.65, −0.74)

0.02

−1.45 (−6.07, 3.16)

0.52

−1.15 (−5.13, 2.83)

0.55

 Weight (kg)

  Unadjusted

0.24 (−3.7, 4.2)

0.90

−2.56 (−6.3, 1.15)

0.17

−0.75 (−5.23, 3.74)

0.74

−1.6 (−5.73, 2.54)

0.44

 Fasting plasma glucose (mmol/l)

  Adjusted

−0.05 (−0.77, 0.67)

0.90

−0.42 (−1.09, 0.24)

0.20

0.09 (−0.77, 0.95)

0.84

0.10 (−0.68, 0.88)

0.79

 Fasting plasma glucose (mmol/l)

  Unadjusted

0.02 (−1.34, 1.37)

0.98

− 0.17 (−1.43, 1.09)

0.79

0.16 (−0.76, 1.07)

0.73

0.44 (−0.45, 1.33)

0.32

  1. Baseline factors adjusted for in dose-response modelling (considered to be potential confounders; Additional File 5; Figure 2) were based on a backward elimination algorithm starting with all baseline measures, retaining those that were significant at the 5% level. Baseline factors adjusted for in dose-response modelling were (a) 12 months INT HbA1c (HbA1c, fat scale score), 12 months INT weight (physical activity, gender, body fat mass, HbA1c, total met minutes per week), and 12 months INT fasting plasma glucose (waist circumference , fasting plasma glucose, body fat mass, fat scale score, and HbA1c); (b) 12 months INT-DPM HbA1c (HbA1c), 12 months INT-DPM weight (baseline BMI), and 12 months INT-DPM fasting plasma glucose (fasting glucose); (c) 24 months INT HbA1c (HbA1c, visceral fat mass, deprivation index, fasting plasma glucose), 24 months INT weight (minutes sitting, weight, family history diabetes), and 24 months INT fasting plasma glucose (age, visceral fat mass, fibre scale score, total MET minutes per week, deprivation index, body fat mass, fasting plasma glucose); and (d) 24 months INT-DPM HbA1c ( total MET minutes per week, HbA1c, EQ5D, deprivation index), 24 months INT-DPM weight (visceral fat mass, ADD QoL, weight, EQ5D, deprivation index, HbA1c, fasting plasma glucose, total MET minutes per week), and 24 months INT-DPM fasting plasma glucose (fasting plasma glucose, body fat mass, physical activity category, BMI, deprivation index). Data is also shown unadjusted for baseline variables